uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Process development for the production of a therapeutic Affibody® Molecule
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Biology Education Centre.
2014 (English)Independent thesis Advanced level (degree of Master (Two Years)), 20 credits / 30 HE creditsStudent thesisAlternative title
Processutveckling för att tillverka en Affibody®-molekyl avsedd för cancerterapi (Swedish)
Abstract [en]

Recently HER3, member of the epidermal growth factor receptor family (EGFR), has been found to play a crucial role in the development of resistance towards inhibitors that are given to patients with HER1- and HER2-driven cancers. As HER3 is up-regulated or over-activated in several types of human cancers, it is of outmost importance that new innovative drugs target its oncologic activity.

The Affibody® Molecule Z08698 inhibits the heregulin induced signalling of HER3 with high affinity (KD~50 pM). As the Affibody® Molecule is small, has high solubility and outstanding folding kinetics, an effective penetration of tumour tissue is suggested together with a rationalized manufacturing process. Further coupling to an albumin binding domain (ABD) expands the plasma half-life of the molecule, hence increasing the molecule's potential of serving as a therapeutic.

A process development for production of Z08698-VDGS-ABD094 has been established, where the molecule is efficiently produced in the E. coli host strain BL21(DE3), through a T7 based expression system. Cultivations were performed with a fed-batch fermentation process and the conditions were further optimized in order to obtain highest expression, while avoiding undesirable modifications like gluconoylations. By employing Design of experiments in combination with multivariate data analysis, a production process resulting in ~3.5 g product/ l culture could be verified. Moreover, thermolysis was evaluated as a suitable method for cell disruption, enabling an easy and cost-effective manufacturing process of the ABD fused Affibody® Molecule.

Place, publisher, year, edition, pages
2014. , 60 p.
Keyword [en]
Affibody® Molecule, HER3, EGFR, HER2, cancer therapy, process development, DOE, multivariate data analysis, E. coli, ABD, plasma half-life, thermolysis, fed-batch, gluconoylation, BL21(DE3), T7 expression system
National Category
Engineering and Technology
Identifiers
URN: urn:nbn:se:uu:diva-218861OAI: oai:DiVA.org:uu-218861DiVA: diva2:697657
External cooperation
Affibody AB
Educational program
Molecular Biotechnology Engineering Programme
Supervisors
Examiners
Available from: 2014-02-20 Created: 2014-02-18 Last updated: 2014-02-20Bibliographically approved

Open Access in DiVA

fulltext(3179 kB)475 downloads
File information
File name FULLTEXT01.pdfFile size 3179 kBChecksum SHA-512
6a208423a9d97219df4ba87fac7c75ba5a54899a2b4ceba8547cb3f35f0548d6a19f03b7f6b2a0c391b5e48b5b63321b488826aff9b0deb277598087f3035362
Type fulltextMimetype application/pdf

By organisation
Biology Education Centre
Engineering and Technology

Search outside of DiVA

GoogleGoogle Scholar
Total: 475 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 604 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf